mhurhangee/ep-ind-claims huggingface dataset:
A formulation selected from: lanthanum carbonate in an amount from 10 to 50 wt% lanthanum, as the element; 10 to 90 wt% diluents; and 0.1 to 6.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 10 to 40 wt% lanthanum, as the element; 40 to 80 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 30 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 30 to 50 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 10 to 30 wt% lanthanum, as the element; 24 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 40 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 27 wt% lanthanum, as the element; 42 to 58 wt% diluents; and 0.1 to 4.0 wt% blending/flow agent(s)-lubricant(s); and wherein the formulation is a chewable formulation that comprises at least one chewable pharmaceutically acceptable excipient. lanthanum carbonate in an amount from 10 to 50 wt% lanthanum, as the element; 10 to 90 wt% diluents; and 0.1 to 6.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 10 to 40 wt% lanthanum, as the element; 40 to 80 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 30 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 30 to 50 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 10 to 30 wt% lanthanum, as the element; 24 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 30 wt% lanthanum, as the element; 40 to 60 wt% diluents; and 0.1 to 5.0 wt% blending/flow agent(s)-lubricant(s); or lanthanum carbonate in an amount from 20 to 27 wt% lanthanum, as the element; 42 to 58 wt% diluents; and 0.1 to 4.0 wt% blending/flow agent(s)-lubricant(s); and wherein the formulation is a chewable formulation that comprises at least one chewable pharmaceutically acceptable excipient.
Multi-storey building with safe means of access and escape in the event of fire, with: - a core zone in which at least one safety staircase and at least one elevator shaft for an elevator and an elevator lobby are located; - horizontal fire- and water-resistant fire barriers, which seal off the core zone in the horizontal direction from surrounding usage areas against fire and water; and - vertical fire and water-resistant fire barriers, which separate the core zone in the vertical direction into core segments and seal off the usage areas in the vertical direction in fire protection segments against fire and water, wherein: - the vertical fire barriers are designed as intermediary floors; - each core segment is protected by a smoke prevention pressure system and is connected to at least the intermediary floor above or below in such a way that the smoke prevention pressure system keeps, besides this core segment, also the above or below adjoining intermediary floor smoke-free in the event of fire; characterised in that the elevator shafts are connected to the outside in each intermediary floor via a first and a second pressure compensation duct (51, 52), wherein the first pressure compensation duct has a check valve which only allows excess pressure to be released to the outside, wherein the second pressure compensation duct has a controllable valve which can be opened and closed, and wherein the valves of the second pressure compensation ducts of all intermediary floors which are located above the burning floor can be closed automatically. - a core zone in which at least one safety staircase and at least one elevator shaft for an elevator and an elevator lobby are located; - horizontal fire- and water-resistant fire barriers, which seal off the core zone in the horizontal direction from surrounding usage areas against fire and water; and - vertical fire and water-resistant fire barriers, which separate the core zone in the vertical direction into core segments and seal off the usage areas in the vertical direction in fire protection segments against fire and water, - the vertical fire barriers are designed as intermediary floors; - each core segment is protected by a smoke prevention pressure system and is connected to at least the intermediary floor above or below in such a way that the smoke prevention pressure system keeps, besides this core segment, also the above or below adjoining intermediary floor smoke-free in the event of fire; characterised in that the elevator shafts are connected to the outside in each intermediary floor via a first and a second pressure compensation duct (51, 52), wherein the first pressure compensation duct has a check valve which only allows excess pressure to be released to the outside, wherein the second pressure compensation duct has a controllable valve which can be opened and closed, and wherein the valves of the second pressure compensation ducts of all intermediary floors which are located above the burning floor can be closed automatically.
An electroless plating method for a resin material, the method comprising step 1: bringing the surface to be treated of the resin material into contact with a pretreatment composition, and step 2: bringing the surface to be treated of the resin material into contact with an electroless plating solution, wherein the pretreatment composition contains 10 mg/L or more of manganese ions and 10 mg/L or more of monovalent silver ions, the pretreatment composition has a pH of 2 or less, the manganese ions are at least one of trivalent manganese ions, quadrivalent manganese ions, permanganate ions and divalent manganese ions in combination with manganese ions of trivalent or higher manganese, and the method not comprising any further catalyst-adding step. step 1: bringing the surface to be treated of the resin material into contact with a pretreatment composition, and step 2: bringing the surface to be treated of the resin material into contact with an electroless plating solution, wherein the pretreatment composition contains 10 mg/L or more of manganese ions and 10 mg/L or more of monovalent silver ions, the pretreatment composition has a pH of 2 or less, the manganese ions are at least one of trivalent manganese ions, quadrivalent manganese ions, permanganate ions and divalent manganese ions in combination with manganese ions of trivalent or higher manganese, and the method not comprising any further catalyst-adding step.
A fuel system for a gas turbine engine comprising: a fuel pump providing fuel flow during engine operation; and a transmission system including an output shaft coupled to drive the fuel pump and an input shaft driven through a mechanical link coupled to a shaft (40, 50) of the gas turbine engine, wherein the output shaft drives the fuel pump at a variable speed that is independent of a rotational speed of the input shaft, wherein the transmission system comprises a hydraulic drive driven by the mechanical link. a fuel pump providing fuel flow during engine operation; and a transmission system including an output shaft coupled to drive the fuel pump and an input shaft driven through a mechanical link coupled to a shaft (40, 50) of the gas turbine engine, wherein the output shaft drives the fuel pump at a variable speed that is independent of a rotational speed of the input shaft, wherein the transmission system comprises a hydraulic drive driven by the mechanical link.
A prosthesis for regeneration of nerves consisting of a core with a length of 5-50 mm made from chitosan with a mean molecular weight of 100-500 kDa and a deacetylation degree of 80-98% which is placed in a sleeve in the shape of a cylinder with a wall thickness of 0.04-1.0 mm and an internal diameter of 1-10 mm, the said sleeve being made from DL-lactide/glycolide copolymer with a molar ratio of 75/25, wherein the sleeve protrudes beyond both core ends, characterised in that the core is made from chitosan in the form of solid fibres with a diameter of 20-40 μm, wherein the fibres in a strained state are placed in the sleeve in parallel to the axis of the said sleeve, and their quantity is from 150 to 22500.
A semiconductor-based SWIR infrared detector sensitive to wavelengths shorter than about 2.5 microns comprising a stack of semiconductor layers based on III-V materials forming a PIN photodiode, said stack comprising at least: - a naked electrical contact, called a lower electrical contact, serving as an optical window; and - a detection layer sensitive to said wavelengths; characterized in that the so-called lower contact is naked and comprises at least one layer of indirect-bandgap III-V material(s) doped n-type, pseudomorphic or lattice matched with a substrate being made of a III-V material InP or GaAs or of silicon or germanium. - a naked electrical contact, called a lower electrical contact, serving as an optical window; and - a detection layer sensitive to said wavelengths;
A method for coating a substrate comprising: a) providing a liquid aqueous coating composition, the composition comprising an acrylic resin as binder, one or more surfactants, a coalescence solvent, and a thickener; b) foaming the liquid aqueous coating composition to obtain a foamed coating composition; c) applying a layer of the foamed coating composition on the substrate; and d) allowing gas to escape from the layer of foamed coating composition and allowing the coating composition to dry to form a homogeneous non-foam dried coating, wherein the liquid aqueous coating composition provided in step a) comprises the acrylic resin in a concentration in the range of from 1 to 20 wt%, comprises the thickener in a concentration in the range of from 0.05 to 2.0 wt%, and has a solids content of at most 25 wt%, based on the total weight of the liquid aqueous coating composition and wherein the aqueous coating composition provided in step a) is a paint, wood stain or varnish. a) providing a liquid aqueous coating composition, the composition comprising an acrylic resin as binder, one or more surfactants, a coalescence solvent, and a thickener; b) foaming the liquid aqueous coating composition to obtain a foamed coating composition; c) applying a layer of the foamed coating composition on the substrate; and d) allowing gas to escape from the layer of foamed coating composition and allowing the coating composition to dry to form a homogeneous non-foam dried coating,
A composition comprising at least one zeolite and a mixture comprising at least one fluoroolefin and at least one R f C≡CX impurity, wherein: (a) R f is a straight-chain perfluorinated alkyl group, and X is H, F, Cl, Br or I; and (b) said at least one zeolite is selected from the group consisting of zeolites having pore opening of at least 4 Angstroms and no more than 5 Angstroms, zeolites having pore opening of at least 5 Angstroms and Sanderson electronegativity of no more than 2.6, and mixtures thereof; provided that said at least one zeolite is not zeolite 4A. (a) R f is a straight-chain perfluorinated alkyl group, and X is H, F, Cl, Br or I; and (b) said at least one zeolite is selected from the group consisting of zeolites having pore opening of at least 4 Angstroms and no more than 5 Angstroms, zeolites having pore opening of at least 5 Angstroms and Sanderson electronegativity of no more than 2.6, and mixtures thereof; provided that said at least one zeolite is not zeolite 4A.
An inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, by administration of the composition to the lungs via pulmonary route, wherein said treatment is performed in a dosage regimen that comprises cycle of multiple sequences of administration by inhalation, said cycle lasting from 10 days to 30 days, wherein each of multiple sequences of administration is performed in a one single day, with 2 to 4 days intervals between sequences, and each of said sequences consists of multiple single dose inhalations separated by a break period lasting at least 5 minutes, and wherein the composition is an inhalable dry powder composition and wherein the composition comprises from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose and wherein the composition provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.
A peptide having the amino acid sequence I: [Yn···Y 1]ZX 1 X 2 X 3 S(p)[W 1 ···Wm] wherein, m equals 1 or 2; n is 5, such that said peptide consists of 11 or 12 amino acid residues; S(p) is a phosphorylated serine residue or a phosphorylated threonine residue; Z is any amino acid residue excepting serine residue or threonine residue; X 1 and X 2 are each a proline residue; X 3 is a hydrophobic amino acid residue selected from the group consisting of alanine, leucine, isoleucine, valine, proline, phenylalanine, methionine, cysteine and tryptophan; Y 1 -Yn is an amino acid sequence present in a substrate of GSK-3 upstream a recognition motif of said natural substrate of GSK-3, said recognition motif being represented by SEQ ID NO:3; and W 1 -Wm are one or two amino acid residues present in said substrate of GSK-3 downstream said recognition motif of said substrate of GSK-3, wherein: said GSK-3 substrate is HSF-1, Y 1 -Y 5 is Lys-Glu-Ala-Pro-Pro, m is 1 or 2, and at least one of W 1 and Wm is proline. m equals 1 or 2; n is 5, such that said peptide consists of 11 or 12 amino acid residues; S(p) is a phosphorylated serine residue or a phosphorylated threonine residue; Z is any amino acid residue excepting serine residue or threonine residue; X 1 and X 2 are each a proline residue; X 3 is a hydrophobic amino acid residue selected from the group consisting of alanine, leucine, isoleucine, valine, proline, phenylalanine, methionine, cysteine and tryptophan; Y 1 -Yn is an amino acid sequence present in a substrate of GSK-3 upstream a recognition motif of said natural substrate of GSK-3, said recognition motif being represented by SEQ ID NO:3; and W 1 -Wm are one or two amino acid residues present in said substrate of GSK-3 downstream said recognition motif of said substrate of GSK-3, said GSK-3 substrate is HSF-1, Y 1 -Y 5 is Lys-Glu-Ala-Pro-Pro, m is 1 or 2, and at least one of W 1 and Wm is proline.
A device for filtering smoke, in particular tobacco and/or cannabis cigarette filter, with a wrap, wherein at least a first section, a second section and a third section are provided in the wrap, wherein the second section is disposed between the first section and the third section, wherein a first nonwoven filter material is provided in the first section; a porous filter material is provided in the second section; and a second nonwoven filter material is provided in the third section; wherein a fourth section is provided in the wrap, wherein the third section is disposed between the second section and the fourth section, and wherein the fourth section is configured in a manner such that a pressure drop over the fourth section is smaller than a pressure drop over the third section as a flow passes through the wrap, characterized in that the wrap is formed by a filter wrap paper, wherein the fourth section comprises a support element that supports the wrap in the region of the fourth section, wherein the porous filter material is activated carbon. a first nonwoven filter material is provided in the first section; a porous filter material is provided in the second section; and a second nonwoven filter material is provided in the third section; wherein a fourth section is provided in the wrap, wherein the third section is disposed between the second section and the fourth section, and wherein the fourth section is configured in a manner such that a pressure drop over the fourth section is smaller than a pressure drop over the third section as a flow passes through the wrap, the wrap is formed by a filter wrap paper, wherein the fourth section comprises a support element that supports the wrap in the region of the fourth section, wherein the porous filter material is activated carbon.
An adhesive tape comprising: a base material; and an adhesive sheet provided on one surface of the base material and comprising cured products of an aqueous acrylic adhesive composition, wherein the adhesive sheet has a porous structure comprising pores, wherein the adhesive tape has a water vapor transmission rate of 3,000 g/m 2 ·day or more and 5,000 g/m 2 ·day or less under conditions of a temperature of 40°C and a relative humidity of 20% in accordance with the ASTM E96, wherein the aqueous acrylic adhesive composition comprises an acrylic resin, a thermal foaming agent, a curing agent and a surfactant, and wherein the thermal foaming agent includes one or more selected from the group consisting of azo dicarbon amide, p,p'-oxybis(benzenesulfonyl hydrazide), p-toluenesulfonyl hydrazide, and sodium bicarbonate. a base material; and an adhesive sheet provided on one surface of the base material and comprising cured products of an aqueous acrylic adhesive composition, wherein the adhesive sheet has a porous structure comprising pores, wherein the adhesive tape has a water vapor transmission rate of 3,000 g/m 2 ·day or more and 5,000 g/m 2 ·day or less under conditions of a temperature of 40°C and a relative humidity of 20% in accordance with the ASTM E96, wherein the aqueous acrylic adhesive composition comprises an acrylic resin, a thermal foaming agent, a curing agent and a surfactant, and wherein the thermal foaming agent includes one or more selected from the group consisting of azo dicarbon amide, p,p'-oxybis(benzenesulfonyl hydrazide), p-toluenesulfonyl hydrazide, and sodium bicarbonate.
A roll system for slivers, comprising at least one stationarily disposed roll and an adjustable roll, wherein the rolls (2, 4) are supported respectively in a first left (3, 5) and a second right frame (3', 5'), wherein, on the left side (3, 5) and the right side (3', 5') of the roll system, the frames are respectively connected to a swivel plate (6, 6'), wherein a point of rotation (7, 7') is disposed in the frames (3, 3') of the stationary roll, so that the adjustable roll is swivelable to the stationary roll, with a sensor for monitoring operational irregularities, characterized in that the sensor, which is formed as a light barrier, recognizes operational irregularities over the width of the roll system in that the light beam is interruptible by an adjusting device or a swivel plate (6, 6').
Method for producing a pressing tool, having steps which follow after one another in the stated order: i) an at least partially hardenable blank being formed to the finished size of a pressing jaw (1.1; 1.2), ii) at least one selected region (12.1; 13.1; 12.2; 13.2) of the surface of the pressing jaw (1.1; 1.2) being impinged on by means of a laser beam in order to form a hardness layer which is close to the surface, wherein the pressing jaw (1.1; 1.2) has a die and at least one end side (3; 4), which is used to form a closing join (120; 130), and the at least one selected region (12.1; 13.1; 12.2; 13.2) lies so as to adjoin at least one edge or so as to be spaced apart from at least one adjacent edge in the transition of the die to the end side (3; 4), such that the edge itself remains unhardened or at least largely unhardened and the edge still has a certain pressure absorption capacity. i) an at least partially hardenable blank being formed to the finished size of a pressing jaw (1.1; 1.2), ii) at least one selected region (12.1; 13.1; 12.2; 13.2) of the surface of the pressing jaw (1.1; 1.2) being impinged on by means of a laser beam in order to form a hardness layer which is close to the surface,
A method for predicting therapeutic response to an IL-31 antagonist in a patient with atopic dermatitis in need of IL-31 antagonist therapy, comprising the steps of: a. isolating circulating cutaneous lymphocyte antigen positive T cells from a biological sample obtained from the patient; b. activating the isolated T cells; c. detecting IL-31 production from the isolated T cells; and d. comparing the amount of IL-31 produced by the T cells from the patient sample to the amount of IL-31 produced from a normal control sample, wherein if a greater amount of IL-31 is detected in the patient sample than the normal control sample, this indicates that the patient will respond to IL-31 antagonist therapy. a. isolating circulating cutaneous lymphocyte antigen positive T cells from a biological sample obtained from the patient; b. activating the isolated T cells; c. detecting IL-31 production from the isolated T cells; and d. comparing the amount of IL-31 produced by the T cells from the patient sample to the amount of IL-31 produced from a normal control sample, wherein if a greater amount of IL-31 is detected in the patient sample than the normal control sample, this indicates that the patient will respond to IL-31 antagonist therapy.
An electroplated coating comprising: a nickel-based metallic electroplated composition comprising 5-15 wt% cobalt, 5-10 wt% chromium, 5-10 wt% aluminum, 0 to 6 wt% molybdenum, 0 to 6 wt% tungsten, 0 to 6 wt% tantalum, 0 to 6 wt% rhenium, 0 to 2 wt% titanium, 0 to 1 wt% zirconium, 0 to 1 wt% hafnium, 0 to 1 wt% yttrium, 0 to 1 wt.% silicon, 0 to 0.2 wt% carbon, 0 to 0.03 wt% boron and the remainder nickel; said composition characterized by a multi-phase microstructure defined at least in part by a gamma nickel solid solution phase (γ-Ni phase) and a gamma prime phase of nickel aluminide (γ'-Ni 3 Al phase) distributed within said γ-Ni phase; said γ'-Ni 3 Al phase including a bimodal microstructure comprising a primary γ'-Ni 3 Al phase and a secondary γ'-Ni 3 Al phase; said secondary γ'-Ni 3 Al phase having a particle size smaller than that of the primary γ'-Ni 3 Al phase; said γ'-Ni 3 Al phase optionally including a uniform distribution within said γ-Ni phase; wherein said γ'-Ni 3 Al phase is contained in an amount that is at least 40 vol% but no greater than 90 vol% to thereby produce an ultimate tensile strength at service temperatures that is greater in comparison to a coating having a MCrAlY composition. a nickel-based metallic electroplated composition comprising 5-15 wt% cobalt, 5-10 wt% chromium, 5-10 wt% aluminum, 0 to 6 wt% molybdenum, 0 to 6 wt% tungsten, 0 to 6 wt% tantalum, 0 to 6 wt% rhenium, 0 to 2 wt% titanium, 0 to 1 wt% zirconium, 0 to 1 wt% hafnium, 0 to 1 wt% yttrium, 0 to 1 wt.% silicon, 0 to 0.2 wt% carbon, 0 to 0.03 wt% boron and the remainder nickel; said composition characterized by a multi-phase microstructure defined at least in part by a gamma nickel solid solution phase (γ-Ni phase) and a gamma prime phase of nickel aluminide (γ'-Ni 3 Al phase) distributed within said γ-Ni phase; said γ'-Ni 3 Al phase including a bimodal microstructure comprising a primary γ'-Ni 3 Al phase and a secondary γ'-Ni 3 Al phase; said secondary γ'-Ni 3 Al phase having a particle size smaller than that of the primary γ'-Ni 3 Al phase; said γ'-Ni 3 Al phase optionally including a uniform distribution within said γ-Ni phase; wherein said γ'-Ni 3 Al phase is contained in an amount that is at least 40 vol% but no greater than 90 vol% to thereby produce an ultimate tensile strength at service temperatures that is greater in comparison to a coating having a MCrAlY composition.